Loading
institutionsInstitution
Fudan University Shanghai Cancer Center
Fudan University Shanghai Cancer Center is China's leading breast cancer centre and the site of first-in-human TROP2 PET imaging.
Overview
Fudan University Shanghai Cancer Center is China's leading breast cancer centre, ranked fifty-fifth in the Newsweek/Statista oncology list, and the site of the first-in-human TROP2 PET imaging study. Shao Zhimin's molecular subtyping of triple-negative breast cancer and the FUTURE umbrella trial built on it, the gallium-68 TROP2 nanobody PET tracer from Shaoli Song, and the highest breast cancer surgical volume in the world are its distinguishing contributions, with Yi-Zhou Jiang, Xichun Hu and Dingwei Ye also listed. OnCo links it to triple-negative breast cancer, to TROP2 as a target and TROP2 PET as a technology, and to Zhongshan Hospital and the Chinese Society of Clinical Oncology. Whether subtype-directed treatment of TNBC improves on a single standard is the question FUTURE was designed to answer. Its TNBC, TROP2 PET and surgery programmes are listed below.
Location
Shanghai, CN
Type
cancer center
Website
Newsweek 2026 oncology rank
#55
OnCo score
#193 · 29 points (5 Newsweek + 0 NCI + 24 from 12 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Fudan University Shanghai Cancer Center, including child institutions. 1,684 works · 18,710 citations · 75% open access · 17% clinical trials · 1% reviews.
Oncology works per year
3282022
3642023
3092024
3762025
3072026
Most works
- Xianjun Yu82 works
- Shaoli Song36 works
- Xiaohua Wu31 works
- Si Shi31 works
- Biyun Wang30 works
- Yi‐Zhou Jiang30 works
- Xichun Hu30 works
- Juefeng Wan29 works
- Jian Zhang28 works
- Zhi‐Ming Shao27 works
Most cited
- TNBC subtyping (FUTURE trial)
- TROP2 PET
- Breast surgery
Dingwei Ye
Professor and Chair, Department of Urology, Fudan University Shanghai Cancer Center
Prostate cancerBladder cancerKidney cancer
Dingwei Ye is China's leading uro-oncologist, whose department runs the Chinese arms of major prostate and bladder cancer trials.
Jin Li
Professor of Medical Oncology, Fudan University Shanghai Cancer Center and Shanghai East Hospital; gastrointestinal oncology
Colorectal cancerGastric cancerTargeted therapy
Principal investigator of FRESCO, the Chinese trial that first proved fruquintinib works in refractory colorectal cancer.
Shaoli Song
Professor and Director, Department of Nuclear Medicine, Fudan University Shanghai Cancer Center
Nuclear medicinePET tracer developmentTROP2 and HER2 PET
Leads the nuclear medicine group behind the first human TROP2 PET imaging, aiming to pick patients for TROP2 ADCs with a scan.
Xichun Hu
Professor of Medical Oncology; Chief, Department of Breast and Urologic Medical Oncology, Fudan University Shanghai Cancer Center
Breast cancerChemotherapyAntibody-drug conjugates
A breast medical oncologist who has led Chinese trials of chemotherapy, CDK4/6 inhibitors, and ADCs in advanced breast cancer.
Yi-Zhou Jiang
Professor of Breast Surgery, Fudan University Shanghai Cancer Center
Triple-negative breast cancerMulti-omicsMetabolomics
Co-architect of the Fudan TNBC subtypes and the metabolic and immune atlases that guide subtype-specific treatment.
Zhi-Ming Shao
Professor of Breast Surgery; Director, Department of Breast Surgery, Fudan University Shanghai Cancer Center
Breast cancer surgeryTriple-negative breast cancer subtypingPrecision oncology
Leads the world's highest-volume breast cancer surgical unit and the FUTURE trial that treats triple-negative breast cancer by molecular subtype.
Similar pages
- Key paperGenomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies
Shares Yi-Zhou Jiang, Zhi-Ming Shao, Zhongshan Hospital, Fudan University, Triple-negative breast cancer (TNBC).
- CompanyHitachi (particle therapy)
Shares Carbon-ion synchrotrons and facilities, Carbon-ion therapy, Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy.
- Key paperCarbon Ion Therapy: A Modern Review of an Emerging Technology
Shares Carbon-ion synchrotrons and facilities, Carbon-ion therapy.
- PairingTROP2 PET → TROP2 ADC selection
Shares TROP2 PET, TROP2, Triple-negative breast cancer (TNBC).
- IdeaAlpha radioligands after ADC failure
Shares TROP2 PET, TROP2, Triple-negative breast cancer (TNBC).
- CompanyToshiba Energy Systems & Solutions
Shares Carbon-ion synchrotrons and facilities, Carbon-ion therapy.
- TechnologyPencil-beam scanning and intensity-modulated proton therapy
Shares Carbon-ion synchrotrons and facilities, Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy.
- InstitutionGunma University Heavy Ion Medical Center
Shares Carbon-ion synchrotrons and facilities, Carbon-ion therapy.
cancers
technologies
targets
drugs
Phase 3ADC